Rheonix Raises $14M in Private Financing | GenomeWeb

NEW YORK (GenomeWeb News) – Rheonix has raised $14 million through a private placement of debt and equity, the Ithaca, NY-based molecular diagnostics company said today.

Rheonix intends to use the funds to remodel its existing space and add a new headquarters to its physical operations. The firm said the remodeling and expansion will enable it to scale up manufacturing capabilities and capacity as it begins production of the Rheonix Chemistry and Reagent Device, or CARD, cartridges for its molecular diagnostic system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.